TipRanks on MSN

Septerna initiated with a buy at Truist

Truist initiated coverage of Septerna (SEPN) with a Buy rating and $34 price target The firm says the company’s SEP-631 is in Phase 1 for chronic ...

NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...
Wall Street Journal

Septerna Inc.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
BioSpace

Septerna to Participate in 8th Annual Evercore Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...

Cantor Fitzgerald Sticks to Their Buy Rating for Septerna, Inc. (SEPN)

Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Septerna, Inc. yesterday and set a price target of $25.00. The company’s shares closed yesterday at $23.77. Claim 60% off TipRanks ...